Plitidepsin - PharmaMar
Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B; PM90001Latest Information Update: 28 Jul 2024
At a glance
- Originator PharmaMar
- Developer Boryung Pharmaceutical; PharmaMar
- Class Anti-inflammatories; Antineoplastics; Antivirals; Depsipeptides; Lactones
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Peptide elongation factor 1 inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma
Highest Development Phases
- Marketed Multiple myeloma
- Phase III COVID 2019 infections
- Phase II Non-Hodgkin's lymphoma; T-cell lymphoma; Urogenital cancer
- No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
- Discontinued Leukaemia; Prostate cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in South Korea (IV)
- 08 Jul 2024 European Commission (EC) revokes the refusal to grant Marketing authorization for plitidepsin in Multiple myeloma
- 24 Apr 2024 PharmaMar terminates the NEREIDA phase II trial in COVID-2019 infections in Belgium, France, Georgia, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain, and UK (IV, Infusion) due to difficulties in patient recruitment (NCT05705167) (EudraCT2022-002489-34)